Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML224 (NCGC00242364) is a TSHR antagonist for the treatment of Graves' orbital disease and Graves' hyperthyroidism.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 12,000 | |||
5 mg | 在庫あり | ¥ 28,500 | |||
10 mg | 在庫あり | ¥ 45,500 | |||
25 mg | 在庫あり | ¥ 88,000 | |||
50 mg | 在庫あり | ¥ 149,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 32,500 |
説明 | ML224 (NCGC00242364) is a TSHR antagonist for the treatment of Graves' orbital disease and Graves' hyperthyroidism. |
ターゲット&IC50 | LHR:>30 μM, TSHR:2.1 μM, HEK293 cells:2.1 μM, FSHR:>30 μM |
In vitro | In human embryonic kidney 293 cells, ML224 exhibits a half-maximal inhibitory concentration (IC50) of 2.1 μM against TSHR after a 20-minute exposure, with a range of 0.001-100 μM. The half-maximal inhibitory concentrations against LH and FSH receptors exceed 30 μM[1]. |
In vivo | ML224(ANTAG3) 2 mg per mouse; administered through intraperitoneal infusion pump; once daily for 3 days) reduces serum FT4 levels and thyroid mRNA of TPO and NIS in mice subjected to prolonged TRH stimulation[1]. |
別名 | NCGC00242364, ANTAG3 |
分子量 | 525.59 |
分子式 | C31H31N3O5 |
CAS No. | 1338824-21-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (152.21 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ML224 1338824-21-7 GPCR/G Protein TSH Receptor NCGC 00242364 NCGC00242364 ML 224 ANTAG-3 ANTAG 3 NCGC-00242364 ANTAG3 ML-224 Inhibitor inhibitor inhibit